Mortality rate of HIV-infected adults on long term combination antiretroviral therapy;Mortalité des adultes infectés par le VIH comparée à la population générale: Données à long terme et selon les lymphocytes CD4

Medecine/Sciences

Volumn 24, Issue 10, 2008, Pages 804-806

  Lewden, Charlotte ^a,b   Chêne, Geneviève ^a,b,c   Morlat, Philippe ^a,b,c   Raffi, François ^d   Dabis, François ^a,b,c   Leport, Catherine ^e  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MEDICAL RESEARCH; MORTALITY; NOTE; POPULATION RESEARCH;

EID: 55049088606     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20082410804     Document Type: Note

References (11)

1. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003 ; 362 : 1267-74.
2. Van Sighem A, Danner S, Ghani AC, et al. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-Infected individuals. J Acquir Immune Defic Syndr 2005 ; 40 : 212-8.
3. Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy : analysis of prospective studies. Lancet 2003 ; 362 : 679-86.
4. 3 on long term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007 ; 46 : 72-7.
5. The data collection on adverse events of anti-HIV drugs study group. Liver-related deaths in persons infected with the human immunodeficiency virus : the DAD study. Arch Intern Med 2006 ; 166 : 1632-41.
6. Gras L, Kesselring AM, Griffin JT, et al. CD4 Cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007 ; 45 : 183-92.
7. Yéni. Prise en charge médicale des personnes infectées par le VIH. Rapport 2006. Recommandations du groupe d'experts. 2006 [cited 2007 march 2007]. Available from : http://www.sante.gouv.fr/htm/ actu/yeni_sida/rapport_experts_2006.pdf
8. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? Br Med J 2007 ; 334 : 76-8.
9. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007 ; 356 : 1723-35.
10. Capeau J, Caron M, Vigouroux C, et al. Les lipodystrophies secondaires aux traitements antirétroviraux de l'infection par le VIH. Med Sci (Paris) 2006 ; 22 : 531-6.
11. Moatti JP, Spire B. Les enjeux économiques et sociaux de l'infection par le VIH à l'ère des multithérapies antirétrovirales : apports des sciences humaines et sociales. Med Sci (Paris) : 2003 ; 19 : 878-84.